J.P. Morgan Sees Novartis's Sales Guidance to 2031 Beating Forecasts
J.P. Morgan analysts say Novartis's guidance through 2031 could push consensus higher, with 2031 sales 2% above estimates. Shares still fell 2.4%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Market Talk, analysts at J.P. Morgan believe the Swiss drugmaker's new sales guidance through 2031 will likely prompt upward revisions to consensus forecasts, according to a research note.
Starting from the $56.57 billion in sales Novartis is expected to post in 2026, the guidance implies 2031 sales of $71.11 billion. JPM calculates this is 2% above consensus. Assuming a 40% core operating margin in 2031, core operating profit would reach $28.45 billion, in line with forecasts. Even so, the stock slid 2.4%.
why it matters
The key point is revenue: the guidance tops expectations, while core operating profit matches consensus. That limits the room for estimate upgrades, and the share reaction suggests investors are cautious.
market impact
Novartis shares: sales guidance above consensus, yet the stock falls, so pressure is mixed.
- Novartis shares mixed — higher sales guidance supports estimates, but the actual share decline weighs on the price
tags
instruments
sources
- Novartis's New Guidance Looks Better Than Expected — Market Talk, 19 November 2026 at 09:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗